Market capitalization | $139.96m |
Enterprise Value | $96.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 0.65 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-211.91m |
Free Cash Flow (TTM) Free Cash Flow | $-158.88m |
Cash position | $219.23m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Kodiak Sciences, Inc. forecast:
6 Analysts have issued a Kodiak Sciences, Inc. forecast:
Dec '23 | |
Current assets | 289 289 |
Fixed assets | 190 190 |
Total Assets | 479 479 |
Dec '23 | |
Equity | 266 266 |
Debt capital | 214 214 |
Total Capital | 479 479 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Head office | United States |
CEO | Victor Perlroth |
Employees | 111 |
Founded | 2009 |
Website | www.kodiak.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.